Opinion|Videos|October 11, 2024
Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis
Key Takeaways
- Belimumab and voclosporin have unique mechanisms of action, impacting their efficacy and safety profiles in lupus nephritis treatment.
- Payers consider clinical outcomes, cost, and value when evaluating belimumab and voclosporin for lupus nephritis management.
Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost-effectiveness in LN management.
Advertisement
Episodes in this series
What is your perspective on the differences between the efficacy and safety profiles of belimumab and voclosporin in the treatment of lupus nephritis (LN)? (Dr. Larranaga and Dr. Wells)
How are payers evaluating the value of belimumab and voclosporin in the management of LN? (Dr. Wigginton)
- What does cost-effectiveness look like in LN management?
Advertisement
Related to this article
The FDA approved talazoparib plus enzalutamide for HRR-mutated metastatic hormone-sensitive prostate cancer after TALAPRO-3 cut progression risk by 52%.
Unclear ownership often leaves survivors without support, and coverage of social and psychological services could close the gap, says Bhatnagar.
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
This system-level initiative significantly increased guideline-concordant venous thromboembolism prophylaxis rates in hospitalized patients through coordinated education, clinical decision tools, audit-feedback, and pharmacist integration.
For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.
Nevena Vicic, MSc, discusses first real-world data showing mRNA-1283 protected adults 65 and older from COVID-19 hospitalization in 2025-2026.
He sees progress in Richter combination therapies, explains how patient goals shape CLL treatment, and reflects on mentoring trainees.
CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in managed care pharmacy.
Advertisement
Advertisement
Trending on AJMC
1
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
2
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPH
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
5